The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Highlights from ELCC 2021
Andrew Robinson, MD, MSc, FRCPC, Queen’s University, Kingston, ON, shares his highlights from ELCC 2021, picking out updates from the CheckMate 9LA study (NCT03215706) and studies on the significance of tumor mutational burden. Dr Robinson also outlines data from a study of a PD-1 inhibitor and chemotherapy in patients with squamous cell lung cancer, and data from the Phase I/II KRYSTAL-1 trial (NCT03785249) investigating the novel KRAS inhibitor, adagrasib. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
